Association of circulating levels of RANTES and −403G/A promoter polymorphism to acute heart failure after STEMI and to cardiogenic shock

Clinical and Experimental Medicine

Volumn 15, Issue 3, 2015, Pages 405-414

  Lipkova, Jolana ^a   Parenica, Jiri ^a,b,c   Duris, Kamil ^a   Helanova, Katerina ^a,b   Tomandl, Josef ^a   Kubkova, Lenka ^a,b,c   Vasku, Anna ^a   Goldbergova Pavkova, Monika ^a  

^a MASARYK UNIVERSITY   (Czech Republic)

^b UNIVERSITY HOSPITAL BRNO   (Czech Republic)

^c ST ANNE S UNIVERSITY HOSPITAL   (Czech Republic)

Author keywords

Acute myocardial infarction; Cardiogenic shock; Chemokines; RANTES

Indexed keywords

GENOMIC DNA; RANTES; BIOLOGICAL MARKER;

ACUTE HEART FAILURE; ADULT; AGED; ARTICLE; CARDIOGENIC SHOCK; CARDIOVASCULAR MORTALITY; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; FEMALE; HEART EJECTION FRACTION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BLOOD LEVEL; SINGLE NUCLEOTIDE POLYMORPHISM; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; BLOOD; COHORT ANALYSIS; GENETICS; HEART FAILURE; MIDDLE AGED; PATHOLOGY; SURVIVAL ANALYSIS;

ADULT; AGED; BIOMARKERS; CHEMOKINE CCL5; COHORT STUDIES; DISEASE PROGRESSION; FEMALE; HEART FAILURE; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PROMOTER REGIONS, GENETIC; SHOCK, CARDIOGENIC; SURVIVAL ANALYSIS;

EID: 84938421578     PISSN: 15918890     EISSN: 15919528     Source Type: Journal    
DOI: 10.1007/s10238-014-0294-5     Document Type: Article

References (47)

1. Amoli MM, Miranda-Filloy JA, Vazquez-Rodriguez TR, Ollier WE, Gonzalez-Gay MA. Regulated upon activation normal T-cell expressed and secreted (RANTES) and epithelial cell-derived neutrophil-activating peptide (ENA-78) gene polymorphisms in patients with biopsy-proven erythema nodosum. Clin Exp Rheumatol. 2009;27:142–3.
2. Appay V, Rowland-Jones SL. RANTES: a versatile and controversial chemokine. Trends Immunol. 2001;22:83–7.
3. Aukrust P, Ueland T, Muller F, Andreassen AK, Nordoy I, Aas H, Kjekshus J, Simonsen S, Froland SS, Gullestad L. Elevated circulating levels of C–C chemokines in patients with congestive heart failure. Circulation. 1998;97:1136–43.
4. Aukrust P, Yndestad A, Smith C, Ueland T, Gullestad L, Damas JK. Chemokines in cardiovascular risk prediction. Thromb Haemost. 2007;97:748–54.
5. Cavusoglu E, Eng C, Chopra V, Clark LT, Pinsky DJ, Marmur JD. Low plasma RANTES levels are an independent predictor of cardiac mortality in patients referred for coronary angiography. Arterioscler Thromb Vasc Biol. 2007;27:929–35.
6. Ciccone MM, Cortese F, Gesualdo M, Riccardi R, Di Nunzio D, Moncelli M, Iacoviello M, Scicchitano P. A novel cardiac bio-marker: ST2: a review. Molecules. 2013;18(12):15314–28.
7. Ellis M, Al-Ramadi B, Hedstrom U, Frampton C, Alizadeh H, Kristensen J. Significance of the CC chemokine RANTES in patients with haematological malignancy: results from a prospective observational study. Br J Haematol. 2005;128:482–9.
8. ESC Guidelines: Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS); European Association for Percutaneous Cardiovascular Interventions (EAPCI), Wijns W, Kolh P, Danchin N, Di Mario C, Falk V, Folliguet T, Garg S, Huber K, James S, Knuuti J, Lopez-Sendon J, Marco J, Menicanti L, Ostojic M, Piepoli MF, Pirlet C, Pomar JL, Reifart N, Ribichini FL, Schalij MJ, Sergeant P, Serruys PW, Silber S, Sousa Uva M, Taggart D. Guidelines on myocardial revascularization. Eur Heart J. 2010;31(20):2501–55.
9. Fryer AA, Spiteri MA, Bianco A, Hepple M, Jones PW, Strange RC, Makki R, Tavernier G, Smilie FI, Custovic A, Woodcock AA, Ollier WE, Hajeer AH. The −403G>A promoter polymorphism in the RANTES gene is associated with atopy and asthma. Genes Immun. 2000;1:509–14.
10. Gear AR, Camerini D. Platelet chemokines and chemokine receptors: linking hemostasis, inflammation, and host defense. Microcirculation. 2003;10:335–50.
11. Hajeer AH, Al Sharif F, Ollier WE. A polymorphism at position −403 in the human RANTES promoter. Eur J Immunogenet. 1999;26:375–6.
12. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med. 2005;352:1685–95.
13. Hoogerwerf J, Tanck M, van Zoelen M, Wittebole X, Laterre PF, van der Poll T. Soluble ST2 plasma concentrations predict mortality in severe sepsis. Intensive Care Med. 2010;36:630–7.
14. Jang Y, Chae JS, Hyun YJ, Koh SJ, Kim JY, Ko MJ, Rim SJ, Shin HJ, Ordovas JM, Lee JH. The RANTES −403G>A promoter polymorphism in Korean men: association with serum RANTES concentration and coronary artery disease. Clin Sci (Lond). 2007;113:349–56.
15. Kala P, Kanovsky J, Rokyta R, Smid M, Pospisil J, Knot J, Rohac F, Poloczek M, Ondrus T, Holicka M, Spinar J, Jarkovsky J, Dusek L. Age-related treatment strategy and long-term outcome in acute myocardial infarction patients in the PCI era. BMC Cardiovasc Disord. 2012;12:31.
16. Kobusiak-Prokopowicz M, Orzeszko J, Mazur G, Mysiak A, Orda A, Poreba R, Mazurek W. Chemokines and left ventricular function in patients with acute myocardial infarction. Eur J Intern Med. 2007;18:288–94.
17. Krohn R, Raffetseder U, Bot I, Zernecke A, Shagdarsuren E, Liehn EA, van Santbrink PJ, Nelson PJ, Biessen EA, Mertens PR, Weber C. Y-box binding protein-1 controls CC chemokine ligand-5 (CCL5) expression in smooth muscle cells and contributes to neointima formation in atherosclerosis-prone mice. Circulation. 2007;116:1812–20.
18. Liu J, Jia YJ, Li XL, Xu RX, Zhu CG, Guo YL, Wu NQ, Li JJ. RANTES gene G-403A polymorphism and coronary artery disease: a meta analysis of observational studies. PLoS ONE. 2012;7:47211.
19. Matsumori A, Furukawa Y, Hashimoto T, Yoshida A, Ono K, Shioi T, Okada M, Iwasaki A, Nishio R, Matsushima K, Sasayama S. Plasma levels of the monocyte chemotactic and activating factor/monocyte chemoattractant protein-1 are elevated in patients with acute myocardial infarction. J Mol Cell Cardiol. 1997;29:419–23.
20. Mause SF, von Hundelshausen P, Zernecke A, Koenen RR, Weber C. Platelet microparticles: a transcellular delivery system for RANTES promoting monocyte recruitment on endothelium. Arterioscler Thromb Vasc Biol. 2005;25:1512–8.
21. McDermott DH, Beecroft MJ, Kleeberger CA, Al-Sharif FM, Ollier WE, Zimmerman PA, Boatin BA, Leitman SF, Detels R, Hajeer AH, Murphy PM. Chemokine RANTES promoter polymorphism affects risk of both HIV infection and disease progression in the Multicenter AIDS Cohort Study. Aids. 2000;14:2671–8.
22. Nakajima K, Tanaka Y, Nomiyama T, Ogihara T, Ikeda F, Kanno R, Iwashita N, Sakai K, Watada H, Onuma T, Kawamori R. RANTES promoter genotype is associated with diabetic nephropathy in type 2 diabetic subjects. Diabetes Care. 2003;26:892–8.
23. Nickel RG, Casolaro V, Wahn U, Beyer K, Barnes KC, Plunkett BS, Freidhoff LR, Sengler C, Plitt JR, Schleimer RP, Caraballo L, Naidu RP, Levett PN, Beaty TH, Huang SK. Atopic dermatitis is associated with a functional mutation in the promoter of the C–C chemokine RANTES. J Immunol. 2000;164:1612–6.
24. Nystrom PO. The systemic inflammatory response syndrome: definitions and aetiology. J Antimicrob Chemother. 1998;41:1–7.
25. Packard RR, Libby P. Inflammation in atherosclerosis: from vascular biology to biomarker discovery and risk prediction. Clin Chem. 2008;54:24–38.
26. Parenica J, Malaska J, Jarkovsky J, Lipkova J, Dastych M, Helanova K, Litzman J, Tomandl J, Littnerova S, Sevcikova J, Gal R, Sevcik P, Spinar J. Pavkova Goldbergova M. Exp Clin Cardiol. 2012;17(4):205–9.
27. Parissis JT, Adamopoulos S, Venetsanou KF, Mentzikof DG, Karas SM, Kremastinos DT. Serum profiles of C–C chemokines in acute myocardial infarction: possible implication in postinfarction left ventricular remodeling. J Interferon Cytokine Res. 2002;22:223–9.
28. Pattison JM, Nelson PJ, Huie P, Sibley RK, Krensky AM. RANTES chemokine expression in transplant-associated accelerated atherosclerosis. J Heart Lung Transplant. 1996;15:1194–9.
29. Pavkova Goldbergova M, Lipkova J, Pavek N, Gatterova J, Vasku A, Soucek M, Nemec P. RANTES, MCP-1 chemokines and factors describing rheumatoid arthritis. Mol Immunol. 2012;52:273–8.
30. Qin X, He Z, Zhao D, Li L, Yuan L. The RANTES gene promoter polymorphisms are associated with the risk of atherothrombotic cerebral infarction in Northern Han Chinese. Clin Chim Acta. 2011;412:1112–5.
31. Rothenbacher D, Muller-Scholze S, Herder C, Koenig W, Kolb H. Differential expression of chemokines, risk of stable coronary heart disease, and correlation with established cardiovascular risk markers. Arterioscler Thromb Vasc Biol. 2006;26:194–9.
32. Schal TJ. Biology of the RANTES/SIS cytokine family. Cytokine. 1991;3:165–83.
33. Schober A, Manka D, von Hundelshausen P, Huo Y, Hanrath P, Sarembock IJ, Ley K, Weber C. Deposition of platelet RANTES triggering monocyte recruitment requires P-selectin and is involved in neointima formation after arterial injury. Circulation. 2002;106:1523–9.
34. Shimpo M, Morrow DA, Weinberg EO, Sabatine MS, Murphy SA, Antman EM, Lee RT. Serum levels of the interleukin-1 receptor family member ST2 predict mortality and clinical outcome in acute myocardial infarction. Circulation. 2004;109:2186–90.
35. Simeoni E, Winkelmann BR, Hoffmann MM, Fleury S, Ruiz J, Kappenberger L, Marz W, Vassalli G. Association of RANTES G-403A gene polymorphism with increased risk of coronary arteriosclerosis. Eur Heart J. 2004;25:1438–46.
36. Song A, Nikolcheva T, Krensky AM. Transcriptional regulation of RANTES expression in T lymphocytes. Immunol Rev. 2000;177:236–45.
37. Szalai C, Duba J, Prohaszka Z, Kalina A, Szabo T, Nagy B, Horvath L, Csaszar A. Involvement of polymorphisms in the chemokine system in the susceptibility for coronary artery disease (CAD). Coincidence of elevated Lp(a) and MCP-1-2518 G/G genotype in CAD patients. Atherosclerosis. 2001;158:233–9.
38. Tavakkoly-Bazzaz J, Amiri P, Tajmir-Riahi M, Javidi D, Khojasteh-Fard M, Taheri Z, Tabrizi A, Keramatipour M, Amoli MM. RANTES gene mRNA expression and its −403G/A promoter polymorphism in coronary artery disease. Gene. 2011;487:103–6.
39. Tereshchenko IP, Petrkova J, Voevoda MI, Taborsky M, Navratilova Z, Romaschenko AG, Maksimov VN, Mrazek F, Petrek M. CCL5/RANTES gene polymorphisms in Slavonic patients with myocardial infarction. Mediators Inflamm. 2011;2011:525691.
40. Van de Werf F, Bax J, Betriu A, Blomstrom-Lundqvist C, Crea F, Falk V, Filippatos G, Fox K, Huber K, Kastrati A, Rosengren A, Steg PG, Tubaro M, Verheugt F, Weidinger F, Weis M, ESC Committee for Practice Guidelines (CPG). Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology. Eur Heart J. 2008;23:2909–45.
41. van Loosdregt J, van Oosterhout MF, Bruggink AH, van Wichen DF, van Kuik J, de Koning E, Baan CC, de Jonge N, Gmelig-Meyling FH, de Weger RA. The chemokine and chemokine receptor profile of infiltrating cells in the wall of arteries with cardiac allograft vasculopathy is indicative of a memory T-helper 1 response. Circulation. 2006;114:1599–607.
42. Virani SS, Nambi V, Hoogeveen R, Wasserman BA, Coresh J, Gonzalez F 2nd, Chambless LE, Mosley TH, Boerwinkle E, Ballantyne CM. Relationship between circulating levels of RANTES (regulated on activation, normal T-cell expressed, and secreted) and carotid plaque characteristics: the Atherosclerosis Risk in Communities (ARIC) Carotid MRI Study. Eur Heart J. 2011;32:459–68.
43. Vogiatzi K, Voudris V, Apostolakis S, Kochiadakis GE, Thomopoulou S, Zaravinos A, Spandidos DA. Genetic diversity of RANTES gene promoter and susceptibility to coronary artery disease and restenosis after percutaneous coronary intervention. Thromb Res. 2009;124:84–9.
44. von Hundelshausen P, Weber KS, Huo Y, Proudfoot AE, Nelson PJ, Ley K, Weber C. RANTES deposition by platelets triggers monocyte arrest on inflamed and atherosclerotic endothelium. Circulation. 2001;103:1772–7.
45. Weinberg EO, Shimpo M, De Keulenaer GW, MacGillivray C, Tominaga S, Solomon S, Rouleau JL, Lee RT. Expression and regulation of ST2, an interleukin-1 receptor family member, in cardiomyocytes and myocardial infarction. Circulation. 2002;106:2961–6.
46. Weinberg EO, Shimpo M, Hurwitz S, Tominaga S, Rouleau JL, Lee RT. Identification of serum soluble ST2 receptor as a novel heart failure biomarker. Circulation. 2003;107:721–6.
47. Yun JJ, Fischbein MP, Laks H, Irie Y, Espejo ML, Fishbein MC, Berliner JA, Ardehali A. Rantes production during development of cardiac allograft vasculopathy. Transplantation. 2001;71:1649–56.